PWR
72
-2
APD
34
-5
MA
51
-4
CLX
43
-7
NTRS
29
2
COST
60
-3
GE
67
-3
SE
50
-2
FMC
39
-2
PFE
33
10
BLK
57
3
NI
50
2
JNJ
32
6
HCP
84
-2
ES
38
2
SWN
60
-6
LMT
54
-3
SHW
46
3
HUM
36
2
AMGN
55
5
PWR
72
-2
APD
34
-5
MA
51
-4
CLX
43
-7
NTRS
29
2
COST
60
-3
GE
67
-3
SE
50
-2
FMC
39
-2
PFE
33
10
BLK
57
3
NI
50
2
JNJ
32
6
HCP
84
-2
ES
38
2
SWN
60
-6
LMT
54
-3
SHW
46
3
HUM
36
2
AMGN
55
5
Financhill
Back

Revance Therapeutics 10K Form

Sell
33

RVNC
Revance Therapeutics

Last Price:
3.78
Seasonality Move:
2.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RVNC News And Ratings

See the #1 stock for the next 7 days that we like better than RVNC

RVNC Financial Statistics

Sales & Book Value

Annual Sales: $234.04M
Cash Flow: $-44.51M
Price / Cash Flow: 0
Annual Sales: $-1.72
Price / Book: 0

Profitability

EPS (TTM): -3.80000
Net Income (TTM): $-323.92M
Gross Margin: $159.68M
Return on Equity: 0%
Return on Assets: -59.15%

Revance Therapeutics Earnings Forecast

Key Revance Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 13 years for RVNC is 68.23%.
  • The Selling, General & Administrative Expenses for RVNC have been equal to 124.87% of Gross Profit Margin.
  • The Research & Development expenses have been 33.93% of Revenue.
  • The Interest Expense is -5.97% of Operating Income.
  • The Net Earning history of RVNC is -138.43% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Revance Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RVNC
CUSIP: 761330
Website: revance.com

Debt

Debt-to-Equity Ratio: -2.83
Current Ratio: 3.8
Quick Ratio: 3.16

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RVNC Technical Analysis vs Fundamental Analysis

Sell
33
Revance Therapeutics (RVNC) is a Sell

Is Revance Therapeutics a Buy or a Sell?